Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies

Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies

Show other versions (1)

Bibliographic Details
Main Author:	Hay, Kevin Anthony
Published:	2013
Online Access:	http://hdl.handle.net/1993/21057

Similar Items

Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies
by: Hay, Kevin Anthony
Published: (2013)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
by: Torsten Tonn, et al.
Published: (2020-06-01)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
by: Natalie Yan-Lin Pang, et al.
Published: (2021-08-01)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
by: Sonia Jangra, et al.
Published: (2021-07-01)

Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants
by: Ahlam Chaqroun, et al.
Published: (2021-06-01)

Breakthroughs in SARS-CoV-2-monoclonal antibodies development
by: Yusuf Muhammed, et al.
Published: (2021-02-01)

Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A.
by: Julie Prigent, et al.
Published: (2010-01-01)

Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays
by: Inesa Hyseni, et al.
Published: (2020-09-01)

Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management
by: Gandhi, R.T, et al.
Published: (2022)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
by: Jiajia Xie, et al.
Published: (2021-08-01)

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
by: Chek Meng Poh, et al.
Published: (2020-06-01)

A human monoclonal antibody blocking SARS-CoV-2 infection
by: Chunyan Wang, et al.
Published: (2020-05-01)

Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants
by: Catherine M. Moore, et al.
Published: (2021-06-01)

Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2
by: Manisha Pandey, et al.
Published: (2021-01-01)

SARS-CoV-2 and Anti-Cardiolipin Antibodies
by: Mazen Jizzini, et al.
Published: (2020-12-01)

Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021
by: Barnett, M.L, et al.
Published: (2022)

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant
by: Cheryl Yi‐Pin Lee, et al.
Published: (2021-01-01)

Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.
by: Helen R Savage, et al.
Published: (2021-07-01)

IgV somatic mutation of human anti–SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity
by: Mayara Garcia de Mattos Barbosa, et al.
Published: (2021-05-01)

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
by: Tyler N. Starr, et al.
Published: (2021-04-01)

Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
by: Isa Murrell, et al.
Published: (2021-01-01)

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
by: Angalee Nadesalingam, et al.
Published: (2021-09-01)

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
by: Asheley P. Chapman, et al.
Published: (2021-05-01)

Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
by: Chunyan Wang, et al.
Published: (2020-05-01)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
by: Susanne Rauch, et al.
Published: (2021-04-01)

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
by: Laurel Goldin, et al.
Published: (2021-11-01)

Dissecting strategies to tune the therapeutic potential of SARS-CoV-2–specific monoclonal antibody CR3022
by: Caroline Atyeo, et al.
Published: (2021-01-01)

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
by: Amandine Mveang Nzoghe, et al.
Published: (2021-04-01)

A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form
by: Vinh T. Dang, et al.
Published: (2013-01-01)

The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection
by: Yong Xia, et al.
Published: (2020-07-01)

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
by: Huibin Lv, et al.
Published: (2020-06-01)

Studies of the conserved neutralising epitopes of human rhinoviruses using monoclonal antibodies
by: Kumar, Arvind
Published: (1989)

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
by: Kening Li, et al.
Published: (2020-11-01)

Identification, isolation, and characterisation of HIV-1 neutralising antibodies
by: Wibmer, Constantinos Kurt
Published: (2017)

Janus Emulsion Biosensors for Anti-SARS-CoV-2 Spike Antibody
by: Li, Jie, et al.
Published: (2022)

Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases
by: Aristo Vojdani, et al.
Published: (2021-01-01)

Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization
by: Rut Valgardsdottir, et al.
Published: (2021-07-01)

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
by: Sandro Halwe, et al.
Published: (2021-07-01)

Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants
by: Chen, H.-W, et al.
Published: (2022)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
by: Baoying Huang, et al.
Published: (2021-07-01)